CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions
- PMID: 19375064
- DOI: 10.1016/j.amjsurg.2008.12.031
CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions
Abstract
Background: Obstructive jaundice is frequently associated with false CA19-9 elevation in benign conditions. The diagnostic accuracy of this tumor marker was evaluated in the present longitudinal study.
Methods: In 128 patients admitted for obstructive jaundice (87 with pancreato-biliary malignancy and 41 benign disease) serum CA19-9 was measured. Statistical analysis of marker levels obtained before and after endoscopic biliary drainage was performed in 60 patients.
Results: Elevated CA19-9 levels (>37 U/mL) were found in 61% of benign cases and 86% of malignancies. After biliary drainage, decrease of serum CA19-9 was observed in 19 of 38 malignant cases and in almost all benign cases (Wilcoxon matched pairs test: P = .207 and P <.001, respectively). Receiver operating characteristic (ROC) analysis identified a cut-off value of 90 U/mL to be associated with improved diagnostic accuracy after biliary drainage (sensitivity 61%, specificity 95%).
Conclusions: In the presence of successfully drained obstructive jaundice, CA19-9 serum levels that remain unchanged or measure more than 90 U/mL are strongly indicative of a malignant cause of obstruction. However, the real clinical utility of this marker remains controversial.
Similar articles
-
Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.Eur J Surg Oncol. 2000 Aug;26(5):474-9. doi: 10.1053/ejso.1999.0925. Eur J Surg Oncol. 2000. PMID: 11016469
-
A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.Am J Gastroenterol. 1999 Jul;94(7):1941-6. doi: 10.1111/j.1572-0241.1999.01234.x. Am J Gastroenterol. 1999. PMID: 10406263
-
[CA19-9 has no value as a tumor marker in obstructive jaundice].Schweiz Med Wochenschr. 1999 Jan 23;129(3):77-9. Schweiz Med Wochenschr. 1999. PMID: 10065510 Review. German.
-
Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?Turk J Gastroenterol. 2003 Sep;14(3):181-4. Turk J Gastroenterol. 2003. PMID: 14655062
-
Endoscopic retrograde cholangiopancreatography for distal malignant biliary stricture.Gastrointest Endosc Clin N Am. 2012 Jul;22(3):479-90. doi: 10.1016/j.giec.2012.04.024. Epub 2012 Jun 13. Gastrointest Endosc Clin N Am. 2012. PMID: 22748244 Review.
Cited by
-
Combined ultrasound endoscopy-guided fine-needle aspiration with DNA methylation of SHOX2 and RASSF1A genes to enhance the auxiliary diagnostic precision of pancreatic cancer.Heliyon. 2024 Jul 3;10(13):e34028. doi: 10.1016/j.heliyon.2024.e34028. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39071574 Free PMC article.
-
High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy.J Cancer. 2019 Jun 9;10(16):3810-3818. doi: 10.7150/jca.31375. eCollection 2019. J Cancer. 2019. PMID: 31333798 Free PMC article.
-
Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer.Clin Cancer Res. 2023 Apr 3;29(7):1267-1278. doi: 10.1158/1078-0432.CCR-22-3526. Clin Cancer Res. 2023. PMID: 36662807 Free PMC article.
-
Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.EBioMedicine. 2019 Apr;42:375-385. doi: 10.1016/j.ebiom.2019.03.056. Epub 2019 Apr 5. EBioMedicine. 2019. PMID: 30956167 Free PMC article.
-
CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer.J Gastrointest Surg. 2013 Dec;17(12):2092-8. doi: 10.1007/s11605-013-2389-9. Epub 2013 Oct 22. J Gastrointest Surg. 2013. PMID: 24146342
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical